Summary
We sought to develop and validate a multivariable prediction model of death in Mexican patients with COVID-19, by using demographic and patient history predictors. We conducted a national retrospective cohort in two different sets of patients from the Mexican COVID-19 Epidemiologic Surveillance Study. To develop the model, we included 264,026 patients tested for SARS-CoV-2 between February 28 and May 30, 2020. To validate the model, 592,160 patients studied between June 1 and July 23, 2020 were included. Patients with a positive RT-PCR for SARS-CoV-2 and complete unduplicated data were eligible. Demographic and patient history variables were analyzed through Multivariable Cox regression models to evaluate predictors to be included in the prognostic scoring system called PH-Covid19. 83,779 patients were included to develop the model; 100,000, to validate the model. Eight predictors (age, sex, diabetes, COPD, immunosuppression, hypertension, obesity, and CKD) were included in the PH-Covid19 scoring system (range of values: −2 to 25 points). The predictive model has a discrimination of death of 0.8 (95%CI:0.796-0.804). The PH-Covid19 scoring system was developed and validated in Mexican patients to aid clinicians to stratify patients with COVID-19 at risk of fatal outcomes, allowing for better and efficient use of resources.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
None
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This article is a retrospective study of an open-source dataset of patients in Mexico. The Ministry of Health of Mexico approved the recollection of information.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Funding: This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
Data Availability
all data is free for your consultation
